NCT00708747View on ClinicalTrials.gov

Biseko Versus Albumin in Systemic Inflammatory Response Syndrome (SIRS) Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 31, 1996

Primary Completion Date

June 30, 2001

Study Completion Date

September 30, 2003

Conditions
Systemic Inflammatory Response Syndrome
Interventions
DRUG

Albumin (5% serum-protein solution containing immunoglobulins)

5% albumin was given intravenously at a volume of 1,000 ml on the first day and 500 ml/day during the following four days.

DRUG

Biseko

Standardised 5% serum-protein solution (Biseko, Biotest, Dreieich, Germany) was given intravenously at a volume of 1,000 ml on the first day and 500 ml/day during the following four days.

Trial Locations (1)

A1090

Medical University Vienna, Vienna

All Listed Sponsors
lead

Medical University of Vienna

OTHER

NCT00708747 - Biseko Versus Albumin in Systemic Inflammatory Response Syndrome (SIRS) Patients | Biotech Hunter | Biotech Hunter